Andere Sprachen Mangoceuticals, Inc.

Aktien

A3DY39

US56270V1061

MGRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 30.05.2024			% 5 Tage	% 1. Jan.
0,415 ^USD	-5,57 %		-20,19 %	+49,87 %

21.05.	Sektor-Update: Aktien des Gesundheitswesens legen am späten Nachmittag zu	MT
21.05.	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets	28.05.
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts	23.05.
Sector Update: Health Care Stocks Advance Late Afternoon	21.05.
Sector Update: Health Care	21.05.
Top Midday Gainers	21.05.
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications	21.05.
Mangoceuticals, Inc. to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications	21.05.
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration	16.05.
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement	02.05.
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care	25.04.
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma	12.04.
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products	12.04.
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC	04.04.
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Top Premarket Gainers	20.03.
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	18.03.
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mangoceuticals, Inc.

Aktien

A3DY39

US56270V1061

MGRX

Andere Sprachen

Filter